Preferred test for individuals of high-risk ethnic backgrounds other than those of African descent. For initial screening for GP6D deficiency, refer to Glucose-6-Phosphate Dehydrogenase (0080135).
Polymerase Chain Reaction/Sequencing
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
Background Information for Glucose-6-Phosphate Dehydrogenase Deficiency (G6PD) Sequencing:
Characteristics: G6PD deficiency can cause chronic hemolytic anemia, food-, drug- and infection-mediated hemolytic anemia, and acute hemolytic anemia with jaundice in the newborn - which can be potentially life-threatening. Ethnic-specific variants are common in individuals of African, Southeast Asian and Mediterranean descent. Most mutations identified to-date have been classified according to the following scheme: Class I - severe enzyme deficiency with chronic non-spherocytic hemolytic anemia (CNSHA); Class II - severe enzyme deficiency with less than 10 percent of the normal activity; Class III - mild to moderate enzyme deficiency (10 to 60 percent of normal activity); and Class IV - very mild to almost normal enzyme activity (greater than 60 percent normal activity with no clinical consequences).
Incidence: Varies by ethnicity. 7 in 10 Kurdish Jewish males; 1 in 6 to 10 African American males; 1 in 7 to 9 Arabic males; 1 in 6 to 16 Southeast Asian males.
Inheritance: X-linked recessive.
Penetrance: Variable depending on mutation and sex.
Cause: Pathogenic mutations in Glucose-6-Phosphate Dehydrogenase (G6PD) gene.
Clinical Sensitivity: Expected greater than 98 percent.
Methodology: Bidirectional sequencing of the entire G6PD coding region and intron-exon boundaries.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region mutations, deep intronic mutations, and large deletions/duplications will not be detected. Mutations in genes other than G6PD are not evaluated.
Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
|Component Test Code*||Component Chart Name||LOINC|
|2007164||G6PD Deficiency (G6PD) Seq Specimen|
|2007165||G6PD Deficiency (G6PD) Seq Interp|
- G-6-PD Deficiency (G6PD) Sequencing
- G6PD Sequencing
- Hemolytic Anemia (G6PD) Sequencing
- Hyperbilirubinemia (G6PD) Sequencing
- RBC G6PD sequencing